title: Targeting substance P and relaxin: A future combination therapy approach for heart failure?
authors.affiliation: Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI, United States; Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, WI 53226, United States. Electronic address: slevick@mcw.edu.
authors.forename: Scott P
authors.initials: SP
authors.lastname: Levick
authors.affiliation: Department of Internal Medicine, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC 27103, United States; Department of Pathology, Section on Comparative Medicine, Wake Forest School of Medicine, Winston-Salem, NC 27103, United States.
authors.forename: Giselle C
authors.initials: GC
authors.lastname: Meléndez
mesh_terms: D000818:Animals; D006321:Heart / Q000502:physiology*; D006333:Heart Failure / Q000503:physiopathology*; D006801:Humans; D013373:Substance P / Q000502:physiology*; D020257:Ventricular Remodeling / Q000502:physiology*
chemical_list: D013373:Substance P